Associated Papers
The impact of C216T and hot spot mutations of the TERT promoter on the clinicopathologic characteristics and S100A10 expression in papillary thyroid carcinoma: a comparative study.
Li P et al.
Diagnostic Pathology, 2025
Clinicopathological Features of CCDC6-RET and NCOA4-RET Fusions in Thyroid Cancer: A Single-Center Retrospective Cohort Study in a Chinese Population.
Wang Z et al.
Thyroid : Official Journal of the American Thyroid Association, 2024
Ultra Deep Sequencing of Circulating Cell-Free DNA as a Potential Tool for Hepatocellular Carcinoma Management.
Higuera M et al.
Cancers, 2022
36010868 (PubMed )
Supplement: cancers-14-03875-s001.zip › Supplementary_Table_S4_Somatic_mutations.xlsx › HCC_patients_mutations
Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans.
Kim SY et al.
Journal of Pathology and Translational Medicine, 2020
Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.
de Unamuno Bustos B et al.
Scientific Reports, 2017
28356599 (PubMed )
Supplement: 41598_2017_606_MOESM2_ESM.xls › Table_S1
Recurrent TERT promoter mutations in non-small cell lung cancers.
Ma X et al.
Lung Cancer (amsterdam, Netherlands), 2014
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Nickerson ML et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations.
Marrone A et al.
Haematologica, 2007
Select a paper to view details